DGAP-News: Xlife Sciences AG
/ Key word(s): Investment/Miscellaneous
Xlife Sciences AG: Xlife Sciences expands its project portfolio Two new project companies offer strong synergy potential About Panmabs GmbH Panmabs aims to become a leading specialist in treating pathologies that arise from epidemic spreading of life-threatening pathogens like the worldwide rising multi-drug resistant bacteria (MRSA) and other infectious threats with lacking or insufficient treatment options. In particular due to the lack of or poor treatment options for such resistant pathogens, the management of Xlife sees enormous market potential in this area. In this context, Panmabs will develop different therapeutic anti-viral and anti-bacterial drug candidates (monoclonal antibodies (mAbs), antibody drug conjugates (ADCs), small molecules) from other third parties and Xlife portfolio companies. About Xarma Life Science GmbH Xarma Life Science GmbH will develop first-in-class functional and modulatory drugs (mAbs and ADCs), targeting complex membrane receptors like G-protein coupled receptors (GPCRs), ion channels and others for the treatment of circulatory, immunologic and oncogenic diseases with unmet medical needs. Within the mentioned fields, Xarma will allocate significant resources for the investigation of new routes towards novel personalised treatment options for currently untreatable diseases. About Xlife Sciences AG Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch For media inquiries: Oliver R. Baumann, CEO Xlife Sciences AG, Tel. +41 44 385 84 60, oliver.baumann@xlifesciences.com
03.12.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | Xlife Sciences AG |
| Klausstrasse 19 | |
| 8008 Zürich | |
| Switzerland | |
| Phone: | 0041 44 385 84 60 |
| E-mail: | info@xlifesciences.ch |
| Internet: | www.xlifesciences.ch |
| ISIN: | CH0461929603 |
| WKN: | A2PK6Z |
| Listed: | Regulated Unofficial Market in Frankfurt, Munich |
| EQS News ID: | 1152456 |
| End of News | DGAP News Service |
1152456 03.12.2020
